Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

10-1-2021

The Burkholderia cenocepacia Type VI Secretion System Effector
TecA Is a Virulence Factor in Mouse Models of Lung Infection
Nicole A. Loeven
Geisel School of Medicine at Dartmouth

Andrew I. Perault
UNC School of Medicine

Peggy A. Cotter
UNC School of Medicine

Craig A. Hodges
Case Western Reserve University

Joseph D. Schwartzman
Geisel School of Medicine at Dartmouth

See next page for additional authors

Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa

Dartmouth Digital Commons Citation
Loeven, Nicole A.; Perault, Andrew I.; Cotter, Peggy A.; Hodges, Craig A.; Schwartzman, Joseph D.;
Hampton, Thomas H.; and Bliska, James B., "The Burkholderia cenocepacia Type VI Secretion System
Effector TecA Is a Virulence Factor in Mouse Models of Lung Infection" (2021). Dartmouth Scholarship.
4217.
https://digitalcommons.dartmouth.edu/facoa/4217

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Authors
Nicole A. Loeven, Andrew I. Perault, Peggy A. Cotter, Craig A. Hodges, Joseph D. Schwartzman, Thomas
H. Hampton, and James B. Bliska

This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/4217

RESEARCH ARTICLE

The Burkholderia cenocepacia Type VI Secretion System Effector
TecA Is a Virulence Factor in Mouse Models of Lung Infection
Nicole A. Loeven,a Andrew I. Perault,b* Peggy A. Cotter,b Craig A. Hodges,c Joseph D. Schwartzman,a
James B. Bliskaa

Thomas H. Hampton,a

Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire, USA

a

University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA

b
c

Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA

Burkholderia cenocepacia is a member of the Burkholderia cepacia complex
(Bcc), a group of bacteria with members responsible for causing lung infections in
cystic ﬁbrosis (CF) patients. The most severe outcome of Bcc infection in CF patients is
cepacia syndrome, a disease characterized by necrotizing pneumonia with bacteremia
and sepsis. B. cenocepacia is strongly associated with cepacia syndrome, making it one
of the most virulent members of the Bcc. Mechanisms underlying the pathogenesis of
B. cenocepacia in lung infections and cepacia syndrome remain to be uncovered. B.
cenocepacia is primarily an intracellular pathogen and encodes the type VI secretion
system (T6SS) effector TecA, which is translocated into host phagocytes. TecA is a deamidase that inactivates multiple Rho GTPases, including RhoA. Inactivation of RhoA by
TecA triggers assembly of the pyrin inﬂammasome, leading to secretion of proinﬂammatory cytokines, such as interleukin-1 b , from macrophages. Previous work with the B.
cenocepacia clinical isolate J2315 showed that TecA increases immunopathology during
acute lung infection in C57BL/6 mice and suggested that this effector acts as a virulence factor by triggering assembly of the pyrin inﬂammasome. Here, we extend these
results using a second B. cenocepacia clinical isolate, AU1054, to demonstrate that TecA
exacerbates weight loss and lethality during lung infection in C57BL/6 mice and mice
engineered to have a CF genotype. Unexpectedly, pyrin was dispensable for TecA virulence activity in both mouse infection models. Our ﬁndings establish that TecA is a B.
cenocepacia virulence factor that exacerbates lung inﬂammation, weight loss, and
lethality in mouse infection models.
IMPORTANCE B. cenocepacia is often considered the most virulent species in the Bcc
because of its close association with cepacia syndrome in addition to its capacity to
cause chronic lung infections in CF patients (1). Prior to the current study, virulence
factors of B. cenocepacia important for causing lethal disease had not been identiﬁed
in a CF animal model of lung infection. Results of this study describe a CF mouse
model and its use in demonstrating that the T6SS effector TecA of B. cenocepacia
exacerbates inﬂammatory cell recruitment and weight loss and is required for lethality and, thus, acts as a key virulence factor during lung infection. This model will be
important in further studies to better understand TecA’s role as a virulence factor
and in investigating ways to prevent or treat B. cenocepacia infections in CF patients.
Additionally, TecA may be the founding member of a family of virulence factors in
opportunistic pathogens.
KEYWORDS Burkholderia cenocepacia, lung infection, type VI secretion

B

urkholderia cenocepacia belongs to a group of Gram-negative bacteria known as
the Burkholderia cepacia complex (Bcc) that exist in the environment and are notorious for causing opportunistic lung infections in immunocompromised patients (1, 2).
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B. cenocepacia infections are most commonly diagnosed in cystic ﬁbrosis (CF) patients;
however, other immunocompromised individuals are also susceptible (2). Bcc infections are difﬁcult to eradicate due to intrinsic antibiotic resistance (1). Patients may
present with asymptomatic, chronic, or severe infection. A severe and rapid onset form
of this disease, cepacia syndrome, is characterized by necrotizing pneumonia and bacteremia, which can lead to sepsis and is often fatal in CF patients. Of the species in the
Bcc, B. cenocepacia accounts for ;45% of isolates from CF patients and is most often
associated with severe disease and cepacia syndrome (3).
CF is a disease resulting from mutations in the cystic ﬁbrosis transmembrane conductance regulator (CFTR) gene. These mutations decrease or prevent chloride ion transport,
causing dehydration of the mucosal layer of the lung and gut epithelium (4). The most
common mutation, present in at least one allele of CFTR in over 90% of CF patients, is the
deletion of phenylalanine 508 (F508del) (5). In the CF lung, dehydrated mucus prevents
proper mucociliary clearance, creating a prime environment for colonization and infection
predominantly by bacterial pathogens. CFTR, however, is not expressed only in epithelial
cells. Innate immune cells also express low levels of CFTR, and it has been shown that lack
of proper chloride ion transport also affects their activities (6). CF neutrophils, for example,
display a variety of defective responses that cause them to be hyperinﬂammatory yet less
bactericidal (7–9). This leads to frequent infections, predominantly bacterial, starting at a
young age that begins the cycle of obstruction, infection, inﬂammation, and exacerbation.
Key bacterial pathogens in CF include Pseudomonas aeruginosa, Staphylococcus aureus,
Haemophilus inﬂuenzae, Stenotrophomonas maltophilia, Achromobacter, and members of
the Bcc (3). Patients are often colonized with bacteria for life, resulting in chronic inﬂammation and cumulative lung ﬁbrosis leading to lung disease, the major cause of death of CF
patients (4, 10).
B. cenocepacia is primarily but not strictly an intracellular pathogen that encodes an
arsenal of virulence factors (1, 2, 11). In situ imaging of infected human and mouse
lung tissue indicates that B. cenocepacia resides primarily in phagocytic cells (12, 13),
but other cells may be infected, including the epithelium (14). One factor implicated in
the pathogenesis of B. cenocepacia is a type VI secretion system (T6SS), designated
T6SS-1 (15–17). T6SS-1 can deliver effectors into host cells (17) or other bacteria (15,
16) that come into contact with B. cenocepacia. A transposon mutagenesis screen identiﬁed T6SS-1 as an important virulence determinant in a chronic rat lung infection
model (17, 18). Studies of macrophages infected in vitro showed that the T6SS-1 is used
by intracellular B. cenocepacia to inactivate the host GTPases Rac1 and Cdc42 (17).
Inactivation of these GTPases in macrophages is associated with reduced phagocytosis
and diminished assembly of NADPH oxidase complexes on phagosomes harboring B.
cenocepacia (17). Additionally, T6SS-1 was shown to be required for B. cenocepacia to
trigger assembly of the pyrin inﬂammasome in macrophages (19). Canonical inﬂammasome assembly leads to caspase-1 processing and subsequent cleavage of gasdermin-D
(GSDMD), pro-interleukin-1 b (pro-IL-1 b ), and pro-IL-18. The mature forms of these proinﬂammatory cytokines as well as IL-1a are subsequently released through GSDMD pores,
and the infected cell may undergo pyroptosis (20–22). Xu et al. (22) discovered that inactivation of Rho GTPases (RhoA/B/C) in macrophages infected with B. cenocepacia in a
T6SS-1-dependent manner is responsible for activation of the pyrin inﬂammasome. This
work established that pyrin, encoded by the Mefv gene, is an intracellular inﬂammasome
sensor that speciﬁcally and indirectly senses inactivation of RhoA/B/C (here referred to as
RhoA) by bacterial effectors and toxins (22–24). Pyrin is the only inﬂammasome sensor
that is preferentially expressed in phagocytes such as neutrophils, monocytes, and activated macrophages (25).
TecA (T6SS effector protein affecting cytoskeletal architecture) was subsequently
identiﬁed as an enzyme encoded by B. cenocepacia that is injected into host phagocytes and inactivates RhoA and Rac1 (26). Additionally, Aubert et al. determined that
TecA deamidates asparagine-41 of RhoA, triggering pyrin activation and inﬂammasome assembly (26). Thus, pyrin inﬂammasome assembly in response to inactivation of
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B. cenocepacia Virulence Factor TecA in Lung Infection

TABLE 1 Bacterial strains used in this study
Source or reference
15
15
This study
This study
This study
George O’Toole

RhoA by TecA is an effector-triggered immune response that is mechanistically similar
to the “guard hypothesis” in plant immunity (26). This work also identiﬁed tecA genes
in other B. cenocepacia strains and tecA-like gene sequences in other bacteria (26). A
putative protein structure for TecA was generated that led to a prediction that cysteine-41 comprises part of a catalytic triad (26). A codon change mutation of cysteine-41
to alanine (C41A) in tecA resulted in loss of catalytic function for TecA and prevented
pyrin inﬂammasome activation in B. cenocepacia-infected macrophages (26).
Studies using acute lung infection models in mice have been carried out with the B.
cenocepacia strain J2315 (BcJ2315) to understand the role of pyrin and TecA in pathogenesis. Xu et al. found by histopathology that an increase in inﬂammation seen in
C57BL/6 mice infected with BcJ2315 was not observed in isogenic Mefv2/2 mice, suggesting that early immune cell inﬂux to the lungs, and subsequent immunopathology,
was pyrin dependent (22). Results of a similar infection procedure showed that TecA
catalytic activity was required for BcJ2315 to cause immune cell recruitment and injury
to the lungs of C57BL/6 mice (26). Although these results suggest that TecA acts as a virulence factor by triggering assembly of the pyrin inﬂammasome, leading to inﬂammatory
cell recruitment and lung immunopathology, other measurements of disease (e.g., pathogen burdens and lethality) have not been examined to conﬁrm this concept. Additionally,
the roles of pyrin and TecA in B. cenocepacia pathogenesis have only been investigated
with BcJ2315 and have not been studied in mice lacking Cftr function, which are known
to have increased susceptibility to lung infections (14, 27, 28). Here, we used B. cenocepacia strain AU1054 (BcAU1054), isolated from the bloodstream of a CF patient in the
United States (15), to study pyrin and TecA and their virulence roles during lung infection
of C57BL/6 mice and mice with the F508del mutation in Cftr.
RESULTS
TecA is a virulence factor during BcAU1054 lung infection in WT mice. To study
B. cenocepacia pathogenesis and immunity, we established a mouse lung infection
model with BcAU1054 (Table 1), a genomovar IIIB, PHDC lineage clinical isolate (15). In
initial experiments, C57BL/6 (wild-type [WT]) mice were mock infected or infected with
5  107 CFU of BcAU1054 by oropharyngeal (o.p.) aspiration, and at 12 h postinfection
immunohistochemistry (IHC) was performed on lung sections using mouse antisera to
B. cenocepacia. As shown in Fig. S1 in the supplemental material, B. cenocepacia antiserum staining was only detected in infected sections and was concentrated in what
appeared to be phagocytes primarily located in the alveoli. This IHC staining pattern
for B. cenocepacia in phagocytes is similar to what has been reported for infected
human and mouse lung sections (12, 13).
To study the role of TecA in pathogenesis, tecA was deleted from BcAU1054 (DtecA
mutant) (Table 1). Groups of WT mice were then infected with BcAU1054 or the DtecA
mutant, and weight and survival were monitored for 14 days. Compared to mice
infected with the DtecA mutant, B. cenocepacia AU1054-infected mice experienced signiﬁcant weight loss (Fig. 1A). The weight loss data in Fig. 1A were used to estimate the
average change in weight from the previous day (log2), and results were displayed by
locally weighted scatterplot smoothing (LOESS) (data not shown). Using the asymptotic Wilcoxon-Mann-Whitney test, it was determined that the mice infected with the
September/October 2021 Volume 12 Issue 5 e02098-21
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Strain name (abbreviated name)
Burkholderia cenocepacia AU1054 (BcAU1054)
Burkholderia cenocepacia AU1054 Dhcp (Dhcp)
Burkholderia cenocepacia AU1054 DtecA (DtecA)
Burkholderia cenocepacia AU1054 DtecA::tecAWT (DtecA::tecA)
Burkholderia cenocepacia AU1054 DtecA::tecAC41A (DtecA::tecAC41A)
Burkholderia cenocepacia J2315 (BcJ2315)
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DtecA mutant regained weight signiﬁcantly earlier than those infected with BcAU1054
(P = 0.007201). Fifty percent of the mice infected with BcAU1054 succumbed to the
disease, while the DtecA mutant was signiﬁcantly less virulent (Fig. 1B), indicating that
TecA is a virulence factor. In different sets of experiments, the percentages of WT mice
that died from BcAU1054 infection ranged from 50% (Fig. 1B) to 20% (Fig. S4B), while
the DtecA mutant was reproducibly avirulent. To demonstrate that the avirulent phenotype of the DtecA mutant was due to loss of TecA enzymatic activity, we complemented the DtecA mutant with wild-type tecA (DtecA::tecAWT) or catalytically inactive
tecA (DtecA::tecAC41A) (Table 1) and carried out mouse infections with the resulting
strains. The avirulent phenotype of the DtecA mutant was complemented by tecAWT
but not tecAC41A, as determined by the weight loss assay (Fig. S2), demonstrating that
the enzymatic activity of TecA is required for virulence. To examine how TecA promotes virulence, CFU assays were performed on lungs and spleens of mice infected
with BcAU1054 or the DtecA mutant over a time course. There was no trend indicating
a difference in the numbers of BcAU1054 and DtecA mutant CFU detected over the
time course up to day 4 (Fig. 1C and D), suggesting that TecA does not increase the
burden of B. cenocepacia in the lung or dissemination to the spleen.
Staining of lung sections with hematoxylin and eosin (H&E) showed mild edema
and peribronchiolar and alveolar inﬂammatory inﬁltrates that appeared more extensive
in the BcAU1054 infections than the DtecA mutant, which had regions that appeared
essentially uninvolved, at both 12 h (Fig. 2A and B) and 3 days (Fig. 2C and D) postchallenge. These results are in line with those of Aubert et al., who used a similar infection
model with BcJ2315 in WT mice and showed that TecA increases inﬁltration of inﬂammatory cells and lung damage at 12 h (26). Semiquantitative scoring of blinding
images by a pathologist indicated that infection by both BcAU1054 and the DtecA mutant caused similar neutrophilic and mononuclear cell inﬁltration and damage in the
September/October 2021 Volume 12 Issue 5 e02098-21

mbio.asm.org 4

Downloaded from https://journals.asm.org/journal/mbio on 20 January 2022 by 75.69.101.51.

FIG 1 TecA enhances weight loss and lethality in WT mice infected with BcAU1054. (A) Weight loss of WT mice infected
by o.p. instillation with 5  107 CFU of BcAU1054 or DtecA mutant. Mice were weighed on D0 and daily for 14 dpi.
Results were pooled from 3 independent experiments. n, total mice infected. Data are represented as percentages of
initial weight. Error bars are standard deviations. Days on which the two groups differed signiﬁcantly (P , 0.05, Welch’s t
test) are marked with an asterisk. (B) Percent survival monitored for 14 dpi of WT mice infected with BcAU1054 or DtecA
mutant. Results were pooled from 3 independent experiments. n, total mice infected. **, P = 0.0054 by log-rank (MantelCox) test. (C and D) Lung (C) and spleen (D) burdens at the indicated dpi in WT mice infected with BcAU1054 or DtecA
mutant. Results are pooled from multiple experiments, and each point represents a value obtained from an individual
mouse and data are represented as number of CFU per gram of tissue. Lines are the medians.

®

FIG 2 Lung inﬂammation in WT mice infected with BcAU1054 or DtecA mutant. (A and C) Representative H&E images of the four
right lung lobe sections from a WT mouse left uninfected (mock) or infected o.p. with 5  107 CFU of BcAU1054 or DtecA mutant at
12 hpi (A) and 3 dpi (C). Light microscopy images are shown at 5 and 20 magniﬁcation. Burdens of BcAU1054 or DtecA mutant in
the infected left lungs of the mice analyzed in panels A and C are shown in panels B and D, respectively. Data are represented as
number of CFU per gram of lung.

bronchioles and alveoli (Table S1). To better quantify the cell inﬁltration, IHC analysis
of lung sections using antibodies to CD11b, Ly6G, and F4/80 was carried out.
Representative images are shown in Fig. 3A and B, and quantitative analysis results
normalized using H-scores are shown in Fig. 3C to E. Results showed that BcAU1054
TecA enhanced neutrophil (CD11b1 Ly6G1) inﬁltration at 12 h postinfection (Fig. 3A, C,
and D) and inﬂammatory monocyte-derived macrophage (CD11b1 F4/801) inﬁltration
at 3 days postinfection (dpi) (Fig. 3B, C, and E). By 3 days postinfection, the neutrophil
numbers in the lungs had decreased to background levels under both infection conditions (Fig. 3B and D), while numbers of inﬂammatory monocyte-derived macrophages
had increased at this time point in response to infection with BcAU1054 (Fig. 3B, C,
and E). These results are consistent with BcAU1054 TecA exacerbating an acute lethal
bronchopneumonia that is dominated by a sustained increase in F4/801 inﬂammatory
monocyte-derived macrophages at day 3 postinfection.
September/October 2021 Volume 12 Issue 5 e02098-21
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FIG 3 TecA enhances recruitment of neutrophils and inﬂammatory monocyte-derived macrophages to lungs in WT mice infected
with BcAU1054. IHC was performed on sections from the right lung lobes analyzed in Fig. 2 using CD11b, Ly6G, and F4/80 antibodies
as indicated. Representative IHC images captured by light microscopy at 5 magniﬁcation are shown. Quantitative IHC image analysis
results normalized using H-scores are shown for CD11b (C), for Ly6G (D), and for F4/80 (E). Each data point represents the H-score for
each of the four different lobe sections. Error bars are standard deviations, and lines are means.

TecA is a virulence factor during BcAU1054 lung infection in CF mice. Previous
studies have indicated that mice lacking Cftr function have increased susceptibility to
B. cenocepacia lung infections (14, 27, 28). To examine this possibility in our infection
model with BcAU1054, CftrF508del (Cftrem1Cwr) mice were obtained from the Case Western
Reserve University CF Mouse Model Core. CftrF508del mice were infected with BcAU1054
or the DtecA mutant as described above. CftrF508del mice infected with BcAU1054 had
increased weight loss compared to the DtecA mutant (Fig. 4A), although this difference
was not signiﬁcant when the data were displayed by LOESS and analyzed using the asymptotic Wilcoxon-Mann-Whitney test (data not shown). TecA was required for lethality (Fig. 4B) without impacting lung or spleen CFU numbers over the ﬁrst 3 days of
infection (Fig. 4C and D). In different sets of experiments, the percentages of CftrF508del
mice that died from BcAU1054 infection ranged from 80% (Fig. 4B) to ;50% (see Fig.
7B), suggesting that the CftrF508del mice are more susceptible to lethal disease than WT
mice. BcAU1054 and DtecA mutant infection increased inﬂammation in the lungs of
CftrF508del mice at 12 h and 3 days postinfection, and the H&E staining results were similar to those obtained in WT mice (compare Fig. 5 with Fig. 2). Lung sections from 12 h
postinfection and 3 days postinfection were also stained for IHC using antibodies to
CD11b, Ly6G, or F4/80 (Fig. 6). Overall, the staining pattern was similar to that in WT
September/October 2021 Volume 12 Issue 5 e02098-21
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mice, although there was no trend toward increased Ly6G1 neutrophils in the
BcAU1054- compared to DtecA-infected lung sections at 12 h (compare Fig. 6D with
Fig. 3D). In summary, BcAU1054 TecA functioned as a virulence factor during lung
infection in CftrF508del mice.
Pyrin is dispensable for B. cenocepacia virulence during lung infection in mice.
Having established that TecA is a virulence factor, experiments were carried out to
determine the importance of the pyrin inﬂammasome for pathogenesis during
BcAU1054 lung infection in mice. To conﬁrm that TecA in BcAU1054 can trigger pyrin
inﬂammasome assembly in WT and CftrF508del backgrounds, in vitro infection experiments were carried out using lipopolysaccharide (LPS)-primed bone marrow-derived
macrophages (BMDMs). WT and CftrF508del BMDMs were left uninfected or infected at a
multiplicity of infection (MOI) of 20 for 90 min with BcAU1054 or DtecA, DtecA::tecAWT,
or DtecA::tecAC41A mutant. Puriﬁed TcdB from Clostridium difﬁcile was used as a positive
control for pyrin inﬂammasome activation. Results of Western blotting and enzymelinked immunosorbent assay (ELISA) were used to monitor the outcomes of the infections or intoxications. In its inactive conformation, murine pyrin is phosphorylated at
serine 205 (p-S205) and serine 241 (29). Dephosphorylation of these sites appears to
trigger activation of pyrin (29, 30). The phosphorylation status of pyrin was determined
by Western blotting BMDM lysates for total pyrin and p-S205 pyrin (30). WT and
CftrF508del BMDMs infected with strain BcAU1054 or DtecA::tecAWT mutant or intoxicated
with TcdB had decreased levels of p-S205 pyrin, whereas those infected with the DtecA
or DtecA::tecAC41A mutant retained p-S205 (Fig. S3A). Pro-IL-1 b was detected by
Western blotting at similar levels in LPS-primed BMDMs under all conditions (Fig. S3A).
ELISA results conﬁrmed that the pyrin inﬂammasome was assembled in response to
TecA or TcdB activity in WT or CftrF508del BMDMs, resulting in processing and release of
IL-1 b by both cell types (Fig. S3B and D).
September/October 2021 Volume 12 Issue 5 e02098-21
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FIG 4 TecA enhances weight loss and lethality in CftrF508del mice infected with BcAU1054. (A) Weight loss of
CftrF508del mice infected o.p. with 5  107 CFU of BcAU1054 or DtecA mutant. Mice were weighed on D0 and
daily for 14 dpi. Results were pooled from 5 independent experiments. n, total mice infected. Data are
represented as percentages of initial weight. Error bars are standard deviations. Days on which the two groups
differed signiﬁcantly (P , 0.05, Welch’s t test) are marked with an asterisk. (B) Percent survival monitored for
14 dpi of CftrF508del mice infected with BcAU1054 or DtecA mutant. Results were pooled from ﬁve independent
experiments. n, total mice infected. ****, P , 0.0001 by log-rank (Mantel-Cox) test. (C and D) Lung (C) and
spleen (D) burden at the indicated dpi in CftrF508del mice infected with BcAU1054 or DtecA mutant. Results were
pooled from multiple experiments, and each point represents a value obtained from an individual mouse. Data
are represented as number of CFU per gram of tissue. Lines are the medians.

®

FIG 5 Lung inﬂammation in CftrF508del mice infected with BcAU1054 or DtecA mutant. (A) Representative H&E
images of the four right lung lobe sections from a CftrF508del mouse left uninfected (mock) or infected o.p. with
5  107 CFU of BcAU1054 or DtecA mutant at 12 hpi (A) or 3 dpi (C). Light microscopy images are shown at
5 and 20 magniﬁcation. Burdens of BcAU1054 or DtecA mutant in the infected left lungs of the mice
analyzed in panels A and C are shown in panels B and D, respectively. Data are represented as number of CFU
per gram of lung.

The CftrF508del mice were crossed to Mefv2/2 mice, and the offspring were infected with
BcAU1054 to investigate the role of the pyrin inﬂammasome for pathogenesis during
BcAU1054 lung infection. As shown in Fig. 7, there was no difference in weight loss (A),
survival (B), or lung (C) or spleen (D) CFU burdens (day 3) when CftrF508del Mef1/2 or
CftrF508del Mefv2/2 mice were infected with BcAU1054. To determine if Mef1/2 mice produce pyrin and secrete IL-1 b to an extent similar to that of the Mefv1/1 background,
CftrF508del Mefv1/1, CftrF508del Mef1/2, and CftrF508del Mefv2/2 BMDMs were prepared and LPS
primed. Western blotting of uninfected BMDM lysates showed that total pyrin was produced in CftrF508del Mefv1/2 BMDMs at the expected ;2-fold smaller amounts than
CftrF508del Mefv1/1 BMDMs (Fig. S3C). The BMDMs were then infected as described above
with BcAU1054, DtecA, or the Dhcp T6SS-1-deﬁcient mutant (Table 1) or intoxicated with
TcdB. ELISA results showed that CftrF508del Mefv1/2 BMDMs released ;2-fold smaller
amounts of IL-1b in response to TecA compared to CftrF508del Mefv1/1 BMDMs (Fig. S3D).
To extend these results to the non-CF background, WT or Mefv2/2 mice were
infected with BcAU1054. As shown in Fig. S4, there was no difference in weight loss
(Fig. S4A), survival (Fig. S4B), or organ CFU burdens at day 3 (Fig. S4C and D) when WT
or Mefv2/2 mice were infected with BcAU1054. Lung sections from these mice infected
September/October 2021 Volume 12 Issue 5 e02098-21
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FIG 6 TecA enhances recruitment of inﬂammatory monocyte-derived macrophages to lungs in CftrF508del mice infected with
BcAU1054. IHC was performed on sections from the right lung lobes analyzed in Fig. 5 using CD11b, Ly6G, and F4/80 antibodies as
indicated. Representative IHC images captured by light microscopy at 5 magniﬁcation are shown. Quantitative IHC image analysis
results normalized using H-scores are shown for CD11b (C), Ly6G (D), and F4/80 (E). Each data point represents the H-score for each
of the four different lobe sections. Error bars are standard deviations, and lines are means.

with BcAU1054 were examined after H&E staining, and no difference in inﬂammatory
cell inﬁltration was evident between WT and Mefv2/2 genotypes (Fig. S5). Production
of pyrin in inﬂammatory cells obtained by bronchoalveolar lavage (BAL) of WT mice
infected with BcAU1054 or the DtecA mutant was conﬁrmed by immunoblotting
(Fig. S6). Thus, our results with BcAU1054 (genomovar IIIB, PHDC lineage) differed from
Xu et al., who reported that inﬂammatory cell inﬁltration into lungs of mice intranasally
infected with BcJ2315 (genomovar IIIA, ET12 lineage) required the pyrin inﬂammasome
(22).
To determine if the discrepancy between our results and those of Xu et al. was due
to B. cenocepacia strain differences, Mefv1/2 and Mefv2/2 mice were infected o.p. with
5  107 CFU of BcJ2315 (Table 1) (22). BcJ2315 appeared to be less virulent than
BcAU1054, as the weight loss was less severe in the infected mice (Fig. S7A).
Nevertheless, there was no difference in weight loss or survival for Mefv1/2 and Mefv2/2
mice infected with BcJ2315 (Fig. S7A and B). In addition, H&E-stained lung sections from
Mefv12 and Mefv2/2 mice showed no difference in inﬂammatory cell inﬁltration at 12 h
and 3 days postinfection with BcJ2315 (Fig. S8A and C). We conﬁrmed by IL-1b ELISA
that our isolate of BcJ2315 triggered assembly of the pyrin inﬂammasome in LPS-primed
BMDMs infected in vitro (Fig. S3E). Thus, the requirement for pyrin in lung inﬂammation
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previously reported with the BcJ2315 strain (22) was not reproduced in our mouse infection model.
DISCUSSION
The underlying basis for the pathogenesis of B. cenocepacia during lung infection
remains to be fully understood. Aubert et al. demonstrated that TecA is critical for
BcJ2315 to cause inﬂammatory cell recruitment and damage to lungs in WT mice (26).
We have extended these results in the following ways. (i) We show that TecA is a virulence factor that exacerbates weight loss and lethality in addition to inﬂammatory cell
recruitment to lungs. (ii) Our results were obtained with BcAU1054, a genomovar IIIB,
PHDC lineage strain distinct from the BcJ2315 genomovar IIIA, ET12 lineage strain, suggesting that TecA is a virulence factor in all members of this species. (iii) We demonstrate
that TecA is a virulence factor in CftrF508del mice, which provide a useful CF animal model.
(iv) Our ﬁndings suggest that the presence of TecA in B. cenocepacia is one reason why
this species is most commonly responsible for cepacia syndrome (1). (v) Our data support
the idea that TecA is the founding member of a family of virulence factors in opportunistic bacterial pathogens, based on the ﬁnding that other opportunistic bacterial pathogens
encode functional TecA orthologs (26), including Chryseobacterium indologenes (31) and
Ochrobactrum anthropi (32). Finally, our results are signiﬁcant because there are only a
few examples of T6SS effectors that have demonstrated anti-host virulence factor activity
in a mammalian infection model (33).
In an unexpected difference from what has been published with BcJ2315 (22), we
were not able to reproduce a requirement for pyrin in inﬂammatory cell recruitment to
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FIG 7 Pyrin is dispensable for BcAU1054 virulence in CftrF508del mice. (A) Weight loss of CftrF508del Mefv1/2 and CftrF508del
Mefv2/2 mice infected o.p. with 5  107 CFU of BcAU1054. Mice were weighed on D0 and daily for 14 dpi. Results were
pooled from 3 independent experiments. n, total mice infected. Data are represented as percent initial weight. Error bars
are standard deviations. (B) Percent survival monitored for 14 days postinfection of CftrF508del Mefv1/2 and CftrF508del Mefv2/2
mice infected with BcAU1054. Results were pooled from three independent experiments. n, total mice infected. ns, not
signiﬁcant by log-rank (Mantel-Cox) test. (C and D) Lung (C) and spleen (D) burden at 3 dpi in CftrF508del Mefv1/2 and CftrF508del
Mefv2/2 mice infected with BcAU1054. Data are represented as number of CFU per gram of tissue. Lines are the medians.

lungs during infection with either BcJ2315 or BcAU1054. Although BcJ2315 appears to
be less virulent than BcAU1054, possibly due to the lack of O-antigen (26), this strain
and BcAU1054 induced inﬂammatory cell recruitment to lungs independent of pyrin in
our infection model. The TecA orthologs are 91% identical between the two strains
(26), and both BcJ2315 and BcAU1054 trigger assembly of pyrin inﬂammasomes in
infected BMDMs. Other experimental differences could be responsible for the discrepancy. While we used o.p. infections with 5  107 CFU, Xu et al. used intranasal infections with the 2-fold higher dose of 1  108 CFU of BcJ2315 (22). Another difference is
that the Mefv2/2 mouse lines used in our study (34) and that of Xu et al. (22) are both
on the C57BL/6 background but independently generated and housed in different animal facilities. It is conceivable that mouse microbiota differences associated with the
different animal facilities used in our study and that of Xu et al. (22) are responsible for
the discrepant results. It will be important to address this possibility in future studies.
Results of studies with BMDMs suggest that B. cenocepacia infection can trigger
T6SS-1-dependent activation of the NLRP3 (17, 35) and noncanonical caspase-11
inﬂammasomes (36, 37) in addition to the pyrin inﬂammasome. We did not detect substantial amounts of IL-1 b released from LPS-primed Mefv2/2 BMDMs infected with
BcAU1054 or BcJ2315, indicating that pyrin-independent inﬂammasomes are not activated during these in vitro infections. In a recent study, C57BL/6 Gsdmd2/2 mice were
infected o.p. with B. cenocepacia strain K65-2, and the authors reported no difference
in survival compared to WT controls (36). These results are consistent with the idea
that cleavage of GSDMD, which would occur downstream of NLRP3, caspase-11, or
pyrin inﬂammasomes, is not essential for the virulence of B. cenocepacia during lung
infection as measured by a survival assay. However, this study reported that after
BcK56-2 infection, Gsdmd2/2 mice had lower lung inﬂammation by H&E staining than
the WT at 48 h postchallenge (36), suggesting that an inﬂammasome is contributing to
immunopathology under these conditions. Additionally, GSDMD has a major role in
restricting replication of BcK56-2 in macrophages, and at 48 h postinfection Gsdmd2/2
mice had higher BcK56-2 organ burdens than the WT (36). Understanding how different inﬂammasome pathways contribute to pathogenesis or host protection during B.
cenocepacia infections is an important goal in the ﬁeld that will require additional
research.
Although we demonstrated that pyrin is produced in BAL cells in response to
BcAU1054 infection of WT mice, we have not attempted to determine if pyrin is activated by TecA in these cells. Aubert et al. obtained evidence that TecA triggers assembly of the pyrin inﬂammasome during systemic B. cenocepacia infection in mice. In an
intraperitoneal infection model, a DtecA mutant exhibited increased spleen burdens
(day 4 postchallenge) and lethality in WT mice compared to the parental BcJ2315 strain
(26). However, in Mefv2/2 mice the DtecA mutant and parent exhibited similar lethality
phenotypes, indicating that TecA triggers assembly of the pyrin inﬂammasome when
infections are initiated systemically, although in this case it leads to a protective host
response. It is possible that host phagocytes differentially control assembly of the
inﬂammasome during B. cenocepacia infections in distinct organs, such that this pathway is activated by pyrin in spleen but not lung.
How TecA promotes virulence during B. cenocepacia lung infections remains to be
determined. TecA does not increase BcAU1054 CFU in lungs, suggesting that it does
not directly counteract bactericidal activities of phagocytes when the infection is initiated by this route. T6SS-1 does not reduce phagocytosis of B. cenocepacia, although it
can inhibit uptake of secondary targets 60 min after infection (38), which is consistent
with the idea that the bacteria exploit the macrophage intracellular environment as a
replicative niche. There is evidence that B. cenocepacia can delay maturation of its
phagosome in macrophages (39, 40), and recently this has been attributed to TecA
(41), but it remains unclear if this activity is essential for survival of the bacteria in host
phagocytes. There is also evidence that T6SS-1 inhibits assembly of NADPH oxidase
complexes on B. cenocepacia-containing phagosomes in macrophages (35, 42).
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However, the fact that only patients with defects in NADPH oxidase activity, such as CF
or chronic granulomatous disease, are highly susceptible to B. cenocepacia infections
strongly argues that these bacteria do not efﬁciently inhibit superoxide production in
phagocytes. In a direct comparison of BcK56-2 and a Burkholderia multivorans clinical
isolate in stimulating the oxidative burst in human macrophages, both strains induced
the oxidative burst at roughly equivalent magnitudes (43). Thus, BcK56-2, which encodes tecA, does not appear to inhibit the oxidative burst more efﬁciently than a B. multivorans strain lacking this effector (26). TecA also does not appear to increase dissemination of B. cenocepacia from the lung, based on spleen or liver CFU numbers of B.
cenocepacia, although this result may be hard to interpret if increased dissemination is
balanced against decreased bacterial survival due to protective pyrin inﬂammasome
responses in spleen or liver.
It is possible that TecA primarily promotes virulence during B. cenocepacia infection by inducing lung immunopathology, as ﬁrst observed by Aubert et al. (26).
Immunopathology leading to lung failure could be the underlying basis for TecA-dependent weight loss and lethality in our infection model. A pyrin inﬂammasome-independent mechanism of immunopathology could be TecA-triggered cytokine or
chemokine production, leading to increased numbers of F4/801 inﬂammatory monocyte-derived macrophages in the B. cenocepacia-infected lung, as we observed by
IHC. CCL2 is produced by a variety of cells and signals for the recruitment of Ccr21
inﬂammatory monocytes out of the bone marrow. We hypothesize that CCL2-elicited
Ccr21 inﬂammatory monocytes play a role in TecA-induced immunopathology, as they
may be the source of the F4/801 cells in lung sections at 3 days postinfection with
BcAU1054, and these cells have been demonstrated to be detrimental to the host in other
lung infection contexts (44). Studies using mice in which Ccr21 inﬂammatory monocytes
are reduced or can be depleted are under way to test this hypothesis.
Bacterial toxins that inactivate Rho GTPases can trigger activation of mitogen-activated protein kinases (MAPKs) in phagocytes (45), representing an alternative mechanism by which TecA could induce immunopathology. It has been shown that TcdA and
TcdB from C. difﬁcile trigger activation of MAPK pathways in monocytes and intestinal
epithelial cells, leading to release of IL-8 (45, 46). The activation of MAPK MK2 (pMK2)
has been demonstrated in epithelial cells as well as in mouse and hamster intestines
(46). IL-8 is a potent neutrophil chemoattractant, and secretion of IL-8 in the gut mucosa leads to injury (45, 46). Interestingly, IL-8 has also been shown to be secreted at
higher levels in CF immune cells than non-CF cells and is present at higher levels in CF
patient BAL samples, suggesting that there are alterations in MAPK signaling in CF
(47, 48).
B. cenocepacia infection in CftrF508del mice does not recapitulate all aspects of the disease in CF patients (e.g., lack of preceding chronic infection and lung necrosis in the context of cepacia syndrome), but we consider it a reasonable and useful CF animal infection
model. This model can be used to uncover the virulence mechanisms of TecA. In addition,
this model can be used to better understand how immune deﬁciencies in CF contribute
to susceptibility to B. cenocepacia lung infection. For example, does dysbiosis of the
microbiota in CF contribute to risk for B. cenocepacia lung infection? Finally, this model
can be used to understand mechanisms of protective immunity to B. cenocepacia, resulting in insights toward development of vaccines and immunotherapeutics to treat or prevent B. cenocepacia infections in the CF patient population.
MATERIALS AND METHODS
Bacterial strains. A list of all Burkholderia cenocepacia strains used in this study can be found in
Table 1. B. cenocepacia overnight cultures were grown in Luria-Bertani (LB) medium shaking cultures at
37°C. The BcAU1054 DtecA and Dhcp deletion mutants were made by allelic exchange (15). For each mutant, ;500 bp 59 to and including the ﬁrst three codons of the gene to delete were fused to ;500 bp 39
to and including the last three codons of the gene by splicing by overhang extension PCR. Fusion products were cloned into the allelic exchange vector pEXKm5 (49), and plasmids were conjugated into
BcAU1054 using Escherichia coli strain RHO3. Merodiploids were selected on 250 m g/ml kanamycin and
grown for 4 h at 37°C with aeration in YT broth (10 g/liter yeast extract, 10 g/liter tryptone), subcultured
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1:1,000 on fresh YT broth, and grown overnight at 37°C with aeration. Following overnight growth, cells
that had resolved the integrated plasmid were selected on YT agar (1.5% agar) containing 25% sucrose
and 100 m g/ml 5-bromo-4-chloro-3-indoxyl- b -D-glucuronide and incubated at 30°C, and deletions were
conﬁrmed via PCR and sequencing of the regions spanning the deletions. Complementation of the
cloned wild-type (WT) gene or tecAC41A was done at transposon insertion sites in the B. cenocepacia chromosome (attTn7 sites) using the pUC18T-mini-Tn7T suite of plasmids (50) and selected by kanamycin resistance. Complementation sequences were cloned into pUC18T-mini-Tn7T-Km containing the constitutive ribosomal S12 subunit gene promoter of Burkholderia thailandensis E264 immediately 59 to the
multiple cloning site (plasmid pUCS12Km, [51]). The tecAC41A sequence was generated using the
Agilent QuikChange II site-directed mutagenesis kit (number 200523). Complementation cassettes
were delivered to the BcAU1054 attTn7 site via triparental mating with E. coli RHO3 strains harboring
pUCS12Km-tecAWT/pUCS12Km-tecAC41A and the transposase helper plasmid pTNS3, and BcAU1054
exconjugants containing these cassettes were selected on agar containing 250 m g/ml kanamycin. All
B. cenocepacia strains used in this study are ampicillin resistant.
Ethics statement. Studies requiring mice for isolation of bone barrow and live mice for infections
were carried out in accordance with a protocol that adhered to the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health (NIH) and was reviewed and approved (approval
number 00002184) by the Institutional Animal Care and Use Committee at Dartmouth College. The
Dartmouth College animal program is registered with the U.S. Department of Agriculture (USDA)
through certiﬁcate number 12-R-0001, operates in accordance with Animal Welfare Assurance (NIH/PHS)
under assurance number D16-00166 (A3259-01), and is accredited with the Association for Assessment
and Accreditation of Laboratory Animal Care International (AAALAC; accreditation number 398). Agematched, sex-matched, and/or littermate controls were used when appropriate.
Mouse strains. Wild-type (WT) C57BL/6J (stock number 000664) mice were purchased from Jackson
Laboratories at 7 weeks of age and rested for a week in our mouse facility before infection. Pyrin knockout mice (Mefv2/2) on the C57BL/6 background were obtained from Jae Chae and Daniel Kastner at the
NIH (34) and bred in the mouse facilities at Dartmouth. Mice with the CftrF508del mutation on the C57BL/6
background were obtained from Case Western Reserve University’s Cystic Fibrosis Mouse Models Core
and bred at Dartmouth. Mefv2/2 and CftrF508del mice were crossed to obtain breeding pairs that were
CftrF508del Mefv1/2 and CftrF508del Mefv2/2. The resulting pups were genotyped and used for infections.
Cell culture. Bone marrow-derived macrophages (BMDMs) were cultured from bone marrow of mice
and cultured as described previously (52, 53). After 7 days of differentiation, the BMDMs were seeded at
a density of 0.8  106 cells/well in 6-well plates in MGM 10/10 medium containing Dulbecco’s modiﬁed
Eagle medium (DMEM) plus GlutaMAX (Gibco) containing 10% fetal bovine serum (FBS) (GE), 10% L929
cell-conditioned medium, 1 mM sodium pyruvate (Gibco), 10 mM HEPES (Gibco) and divided into 6-well
plates at a density of 0.8  106 cells/well in a total volume of 3 ml. The BMDMs were primed with
100 ng/ml O26:B6 Escherichia coli LPS (Sigma) and incubated overnight at 37°C with 5% CO2.
Macrophage infections. Overnight (16 h) cultures of B. cenocepacia were subcultured 1:100 in fresh
LB on infection day and shaken at 37°C until the cultures reached mid-log phase (optical density at 600
nm [OD600] = 0.300). Cultures were then pelleted, the LB was removed, and the bacteria were resuspended in phosphate-buffered saline (PBS) to the original volume. The bacterial suspensions were then
diluted to an MOI of 20 in warmed, serum-free MGM 10/10. As a positive control for pyrin inﬂammasome
activation, the glucosyltransferase toxin from Clostridium difﬁcile TcdB (List Biological Laboratories, Inc.)
was also diluted to 0.1 m g/ml in warmed serum-free MGM 10/10. The BMDMs were washed once in
warm 1 PBS, and 3 ml fresh serum-free MGM 10/10 was added with bacteria and TcdB to the appropriate wells. The plates were then centrifuged for 5 min at 1,000 rpm to bring the bacteria and the cells
into contact on the bottom of the wells. The plates were incubated at 37°C with 5% CO2 for 90 min. Cell
supernatants were collected for cytokine ELISAs and lactate dehydrogenase (LDH) assays. The BMDMs
were lysed using mammalian protein extraction reagent (M-PER; Thermo Scientiﬁc) with added
cOmplete, Mini (Roche) protease inhibitor and PhosSTOP (Roche) phosphatase inhibitor.
Protein analysis by SDS-PAGE and Western blotting. Five to ten micrograms of protein from the
cell lysates was run on 4 to 12% NuPAGE Bis-Tris SDS-PAGE gels (Invitrogen by ThermoFisher Scientiﬁc)
and transferred to polyvinylidene diﬂuoride membranes (ThermoFisher Scientiﬁc) using an iBlot 2 gel
transfer device (Life Technologies). Membranes were blocked in 5% nonfat dairy milk and incubated
with primary antibodies overnight. The primary antibodies used are rabbit-anti-mouse monoclonal total
pyrin antibody (ab195975; abcam), rabbit-anti-mouse monoclonal antibody phospho-serine 205
(ab201784; abcam), rabbit-anti-mouse/human IL-1 b (number 12242; Cell Signaling), and rabbit-antimouse/human polyclonal b -actin (number 4967; Cell Signaling). Horseradish peroxidase-conjugated
anti-rabbit antibody (Jackson Laboratory) was used as a secondary antibody. Proteins were visualized
using chemiluminescent detection reagent (GE Healthcare) on an iBright FL1500 (ThermoFisher
Scientiﬁc).
IL-1b quantiﬁcation. IL-1 b in BMDM supernatants was quantiﬁed using a murine ELISA kit (MLB00C;
R&D Systems) by following the manufacturer’s instructions.
Tail genotyping. Genomic DNA was isolated from mouse tail pieces (clipped at time of weaning) by
digestion overnight at 55°C in 500 m l lysis buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 200 mM NaCl, 0.2%
SDS, 100 m g/ml proteinase K [VWR]). The supernatant was collected by centrifugation (14,000 rpm, 10 min,
room temperature), and DNA was precipitated with 500 m l 100% isopropanol. After centrifugation
(14,000 rpm, 10 min, room temperature), the pellets were washed once with 70% ethanol, air dried for 20
min, and dissolved in 200 m l TE buffer at 55°C for 20 min. PCR was performed with the following primers:
CTGCCCAGAGAAAGGTGATT, WT F (ATCAAAGAAAATATCATCTTT), Cftr WT R (GGACGGTATCATCCCTGAAA),
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Cftr F508del F (ATCAAAGAAAATATCATTGGT), Cftr F508del R (ATGGACGGTATCATCCCTGA), internal control
F (CTAGGCCACAGAATTGAAAGATCT), internal control R (GTAGGTGGAAATTCTAGCATCATCC), Mefv WT
F (TGGAAATGGGAGTCCAGAAA), Mefv WT R (ACCTACCTGTGGGGTCACTG), Mefv KO F (GGGGGAA
CTTCCTGACTAGG), and Mefv KO R (CTGCCCAGAGAAAGGTGATT). To genotype the mouse Cftr gene,
each tail genomic DNA (gDNA) sample was ampliﬁed by PCR in two reactions: one with WT Cftr primers plus internal control and another with F508del Cftr primers plus internal control. To genotype
the murine Mefv gene, each tail gDNA sample was ampliﬁed by PCR in two reactions: one with WT
Mefv primers and another with the Mefv KO primers. PCR products were analyzed by agarose gel
electrophoresis.
Mouse infections. Overnight (16-h) cultures of B. cenocepacia were subcultured 1:100 in fresh LB on
infection day and shaken at 37°C until the cultures reached mid-log phase (OD600 = 0.300). To prepare
the cultures for inoculation, the appropriate volume of culture was centrifuged at 14,000 rpm for 5 min.
The LB was removed, the pellets were combined using a small volume of sterile 1 PBS if the original
culture volume exceeded the volume of one tube, and the cultures were pelleted again at 14,000 rpm
for 5 min. The remaining supernatant was carefully aspirated and the pellet was resuspended in sterile
1 PBS to a ﬁnal volume for 50 m l/dose. The inoculum was serially diluted, plated on LB plates, grown
overnight at 37°C, and counted to ensure the dose was correct for each B. cenocepacia strain used.
Both male and female mice 6 to 12 weeks of age were anesthetized with isoﬂurane and inoculated
via the o.p. route with one 50 m l dose of 5  107 CFU of B. cenocepacia or PBS (mock) using a pipette.
Mice were weighed immediately following instillation, and weight was monitored at 24-h intervals from
time of instillation throughout the experiment. Mice were monitored for survival for 14 days and were
checked 3 times a day and euthanized if moribund. At the indicated time points after infection mice
were euthanized with CO2 or Euthasol with the help of a veterinarian. Tissues including lungs, bronchoalveolar lavage ﬂuid (BALF), liver, and spleen were collected. BALF was collected by inserting a needle into the trachea, removing the lungs and trachea together, and ﬁlling the lungs with sterile 1 PBS
once with 1 ml and twice after with 500 m l, slowly aspirating and massaging the lungs to recover as
much BALF as possible. The cells in the BALF were counted and aliquots of each sample were lysed with
either NP-40 (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40) to release intracellular bacteria for subsequent serial dilutions and plating for CFU or M-PER (with protease and phosphatase inhibitors as
described above) to generate whole-cell lysates. The protein concentrations of the BALF lysates were
quantiﬁed, run on SDS-PAGE gels, and used for Western blotting.
To prepare B. cenocepacia antisera, a C57BL/6J mouse was infected as described above, except the
route was intranasal and the dose was 1  108 CFU of BcAU1054. At day 15 the infection was repeated
with a dose of 5  107 CFU of BcAU1054. At day 28 the mouse was euthanized and serum was collected
and used for IHC along with control serum collected from a naive C57BL/6J mouse.
Lung ﬁxation, parafﬁn embedding, and H&E and IHC staining. Lungs were harvested and the left
lungs were used for organ burden (see below) and right lungs were inﬂated with 10% neutral buffered
formalin (Fisher Scientiﬁc) and left submerged in formalin for at least 24 h. The right lungs were then dissected into the four different lobes and placed in cassettes submerged in 70% ethanol. The four right
lobes for each lung were parafﬁn embedded and sectioned by the DHMC pathology core. The four lobe
sections for each right lung arranged side-by-side on a slide were then stained with hematoxylin and eosin (H&E) for histopathology or were stained to detect speciﬁc cell subsets with antibodies suitable for
IHC, Ly6G (ab238132; abcam), CD11b (ab133357; abcam), and F4/80 (D2S9R) (number 70076; Cell
Signaling), followed by diaminobenzidine (DAB)-conjugated secondary antibody. Alternatively, sections
were stained with BcAU1054 antisera and DAB-conjugated secondary antibody to detect the bacteria.
Microscopy and pathological analysis. H&E and IHC images of the four lobe sections for each right
lung were captured on a Zeiss Axioskop 2 light microscope with a SPOT Insight sCMOS camera (SPOT
Advanced Software) maintained by the Dartmouth microscopy core at 5, 10, 20, and 40 magniﬁcation (Plan Neoﬂuar objectives). H&E images of the four lobes from each right lung were blinded and
analyzed by Joseph Schwartzman using standard pathological criteria for inﬂammation and damage.
Semiquantitative H&E scoring and quantitative IHC staining image analysis were performed by
HistoWiz. Slides were scanned and the blinded H&E images of the four lobes from each right lung were
subjected to semiquantitative scoring of inﬂammation and damage as described previously (54). Lesion
severity was evaluated on a minimal, mild, moderate, and marked scale, and lesion distribution was classiﬁed as focal, multifocal, or diffuse (see Table S1 in the supplemental material). Images of the four lung
lobe sections from each right lung on a scanned IHC slide were subjected to analysis, and cellular quantiﬁcation was performed to identify total cells and percentages of DAB-positive cells classiﬁed by weak,
medium, or intense stain. Values were normalized by H-score, calculated as 1 (% weak stain) 1 2 (%
medium stain) 1 3 (% intense stain).
Organ burden. Organs were collected in stomacher bags, weighed, and placed on ice. Five milliliters
of sterile 1 PBS was added to full (left and right) lungs and livers, and 2.5 ml of sterile 1 PBS was
added to spleens and left lungs. Organs were homogenized by rolling out by hand and then by use of a
Stomacher 80 Biomaster (Seward) on high setting for 2 min. For lungs this homogenization method was
done twice to increase homogenization of the tissue. The homogenates were then serially diluted in
sterile, 1 PBS and plated on LB or LB plates with 100 m g/ml ampicillin. The plates were incubated at
37°C, and the colonies were counted at least 24 h later. Data are displayed as number of CFU per gram
of tissue.
Statistical analysis. GraphPad Prism was used to perform statistical analyses. IL-1 b ELISA data were
analyzed by one-way or two-way analysis of variance (ANOVA; Tukey’s multiple-comparison test) or
Mann-Whitney test. Analysis of the weight loss data was performed by Thomas H. Hampton in the R
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statistical programming language including ggplot2. Asymptotic Wilcoxon-Mann-Whitney tests were
performed using the coin package. Weight loss data were also analyzed using Welch’s t test. Survival
data were analyzed using the log-rank (Mantel-Cox) test. CFU data were analyzed by Mann-Whitney test.
Additional details for each experiment can be found in the ﬁgure legends.
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